NKGen Biotech Inc. (NASDAQ: NKGN)
$0.88
-0.0487 ( -5.24% ) 240.9K
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.
Market Data
Open
$0.88
Previous close
$0.93
Volume
240.9K
Market cap
$23.14M
Day range
$0.88 - $1.03
52 week range
$0.78 - $6.70
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Feb 14, 2024 |
4 | Insider transactions | 1 | Feb 14, 2024 |
4 | Insider transactions | 1 | Feb 14, 2024 |
4 | Insider transactions | 1 | Feb 14, 2024 |
8-k | 8K-related | 16 | Feb 12, 2024 |
8-k | 8K-related | 15 | Feb 08, 2024 |
8-k | 8K-related | 14 | Jan 22, 2024 |
8-k | 8K-related | 14 | Jan 12, 2024 |
8-k | 8K-related | 14 | Jan 08, 2024 |
8-k | 8K-related | 14 | Dec 28, 2023 |